Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous studies have demonstrated that intensive blood pressure (BP) lowering treatment reduces the risk of all-cause mortality and provides greater vascular protection for patients with hypertension. Whether intensive BP lowering treatment is associated with such benefits in patients with type 2 diabetes mellitus remain unknown. We aimed to clarify these benefits by method of meta-analysis. METHODS: The PubMed, EMBASE, Science Citation Index and Cochrane Library databases were searched to identify randomized controlled trials (RCT) that fulfilled study inclusion criteria. Two investigators independently extracted and summarized the relevant data of the included trials. Random-effects model was applied to calculate the estimates of all effect measures. RESULTS: We included 16 RCTs and our meta-analysis showed that intensive BP lowering treatment vs less intensive BP lowering treatment resulted in significant reductions in the all-cause mortality risk [relative risk (RR), 0.82; 95% CI, 0.70-0.96], major CV events (RR, 0.82; 95% CI, 0.73-0.92, MI (RR, 0.86; 95% CI, 0.77-0.96), stroke (RR, 0.72; 95% CI, 0.60-0.88, CV death (RR, 0.73; 95% CI, 0.58-0.92) and albuminuria progression (RR, 0.91 95% CI, 0.84-0.98). However, intensive BP lowering treatment had no clear effect on non-CV death (RR, 0.97; 95% CI, 0.79-1.20), heart failure (HF) (RR, 0.88; 95% CI, 0.71-1.08) or end-stage kidney disease (ESKD) (RR, 1.00; 95% CI, 0.75-1.33). Subgroup analysis showed that the reduction in all cause-mortality was consistent across most patient groups, and intensive BP lowering treatment had a clear benefit even in patients with systolic blood pressure lower than 140 mm Hg. However, the benefit differed in patients with different CV risk (≥10%: RR, 0.77, 95%CI, 0.64-0.91; <10%: RR, 1.04, 95%CI, 0.84-1.29; Phetero = 0.028). CONCLUSIONS: Our data indicate that intensive BP lowering treatment provides greater benefits than less intensive treatment among patients with type 2 diabetes mellitus. Further studies are required to more clearly evaluate the benefits and harms of BP targets below those currently recommended with intensive BP lowering treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although stroke was significantly reduced (HR, 0.59; 95% CI, 0.39–0.89; P = .01).204–206”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [205]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neither the ACCORD BP trial nor subanalyses of other large BP trials have shown that targeting a systolic BP <120 mm Hg (compared with <140 mm Hg) reduces risk of the composite outcome of fatal and nonfatal major CV events in persons with T2D”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [205]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Cited by
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Packer, M. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.04.016 · Cited by 214
“because even intensive control of blood pressure does not prevent serious renal events in type 2 diabetes.(3) SGLT2 inhibitors alleviate the increased intraglomerular filtration pressure that has been implicated in the genesis of”
BackgroundChinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 197
Self-citationPredicting and preventing heart failure in type 2 diabetes
Pandey, A., Khan, M. S., Patel, K. V., Bhatt, D. L., & Verma, S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00128-6 · Cited by 92
Tesfaye, W. H., Erku, D., Mekonnen, A. B., Tefera, Y. G., Castelino, R. L., Sud, K., Thomas, J., & Obamiro, K. O. (2021) · Journal of Nephrology · doi:10.1007/s40620-020-00895-x · Cited by 62
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.002 · Cited by 62
Arellano-Buendía, A. S., Castañeda-Lara, L. G., Loredo-Mendoza, M. L., García‐Arroyo, F. E., Rojas‐Morales, P., Argüello-García, R., Juárez-Rojas, J. G., Tapia, E., Pedraza‐Chaverrí, J., Sánchez‐Lozada, L. G., et al. (2020) · Antioxidants · doi:10.3390/antiox9111134 · Cited by 49
“Besides, a meta-analysis previously reported that the benefit of lowering blood pressure levels includes reduction of the risk of CVD, coronary heart disease, stroke, diabetes, heart failure, and the progression of albuminuria [31].”
BackgroundChronic Kidney Disease among Diabetes Patients in Ethiopia: A Systematic Review and Meta-Analysis
Shiferaw, W. S., Akalu, T. Y., & Aynalem, Y. A. (2020) · International Journal of Nephrology · doi:10.1155/2020/8890331 · Cited by 51
“In addition, another metaanalysis study reported that diabetic patients may benefit more from intensive BP-lowering strategies to provide protection against kidney failure events in patients with diabetes [82, 83].”
BackgroundSabuncu, T., Sönmez, A., Eren, M. A., Sahin, I., Çorapçioğlu, D., Üçler, R., Akin, Ş., Haymana, C., Demirci, İ., Atmaca, A., et al. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.11.001 · Cited by 34
Kaul, S. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14648 · Cited by 22
Intensive blood pressure lowering: a practical review
Camafort, M., Redón, J., Pyun, W. B., & Coca, A. (2020) · Clinical Hypertension · doi:10.1186/s40885-020-00153-z · Cited by 20
“[22] aimed to clarify whether intensive BP lowering was associated with benefits in patients with type 2 diabetes mellitus.”
BackgroundBaffour-Awuah, B., Dieberg, G., Pearson, M. J., & Smart, N. A. (2020) · International Journal of Cardiology Hypertension · doi:10.1016/j.ijchy.2020.100040 · Cited by 22
“In people with diabetes, intensive BP treatment offers greater vascular protection [21], a significant reduction in all-cause mortality, albuminuria progression and CV events [19] and significant risk reductions for MCEs [17].”
BackgroundResultValensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.07.003 · Cited by 20
“According to a recent meta-analysis, reducing systolic BP to < 130 mmHg was associated with significant reductions in CV events and all-cause mortality [187].”
MethodD’Anci, K. E., Tipton, K. N., Hedden-Gross, A., Rouse, B., Hermanson, L., & Fontanarosa, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2037 · Cited by 20
Ioannidou, E., Shabnam, S., Abner, S. C., Kaur, N., Zaccardi, F., Ray, K. K., Seidu, S., Davies, M. J., Khunti, K., & Gillies, C. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102782 · Cited by 22
Adamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 21
Chinese expert consensus on the management of hypertension in adults with type 2 diabetes
Pan, X., He, H., Bao, Y., Bi, Y., Chen, L., Chen, X., Fang, H., Feng, W., Gao, L., Guo, L., et al. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12655 · Cited by 14
“31 The Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events (ESPRIT)trialdemonstratedadditionalprotectionagainstcardiovascu-lar death by controlling systolic blood pressure lower than 120 mmHg (very intensive target), comparing to the conventional…”
InfluentialSelf-citationHou, T., Li, M., Lin, H., Zhao, Z., Lu, J., Wang, T., Xu, Y., Wang, W., Bi, Y., Ning, G., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac354 · Cited by 20
International Guidelines for Hypertension: Resemblance, Divergence and Inconsistencies
Justin, J., Fayol, A., Bruno, R. M., Khettab, H., & Boutouyrie, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071975 · Cited by 15
“The fact that more recent meta-analyses [13,14] call for stricter BP control in T2D patients is interesting.”
BackgroundRecent advances in managing primary hypertension
Leontsinis, I., Mantzouranis, M., Tsioufis, P., Andrikou, I., & Tsioufis, C. P. (2020) · Faculty Reviews · doi:10.12703/b/9-4 · Cited by 12
Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction
Packer, M., Testani, J. M., Butler, J., Zannad, F. M., Lam, C. S. P., Vaduganathan, M., Fang, J. C., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.086 · Cited by 15
“84–93 Even when the analysis was restricted to patients with preexisting chronic kidney disease, intensive antihypertensive therapy did not reduce the incidence of progression of kidney disease, unless patients had substantial proteinuria, 94 a finding with minimal relevance to most patients with…”
SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?
Savage, P., Dixon, L., Grieve, D., & Watson, C. J. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000637 · Cited by 8
“41,42,43”
Iyen, B., Vinogradova, Y., Akyea, R. K., Weng, S. F., Qureshi, N., & Kai, J. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01736-9 · Cited by 7
Tong, P. C.-Y., Chan, S. C.-P., Chan, W. B., Ho, K. K. L., Leung, G. T.-C., Lo, S. H.-K., Mak, G. Y. K., & Tse, T.-S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103403 · Cited by 8
“, attaining an SBP of <130 mmHg from a baseline of <140 mmHg, was shown to further reduce the risk of all-cause mortality [31].”
BackgroundType 2 diabetes mediated heart failure: focus on early recognition and clinical strategies
Chen, X., Li, W. S., Zheng, J.-W., Huang, M., Wang, J., & Wu, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630686 · Cited by 7
“Notably, intensive blood pressure lowering (systolic blood pressure less than 120 mmHg) did not provide additional bene fi ts in reducing the risk of HF compared to a target of less than 140/90 mmHg (146).”
Self-citationLong, W., Wang, X., Lu, L., Wei, Z., & Yang, J. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01440-4 · Cited by 3
Diabetes and Cardiovascular Disorder
Priya, S. S., & Ebenezar, K. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-0027-3_3 · Cited by 3
In emergency hypertension, could biomarkers change the guidelines?
Tahlawi, M. E., Ismail, M. F., Eldamanhory, A., Khorshed, A., & Salem, S. M. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03785-3 · Cited by 3
“The risk of albuminuria progression was assessed in meta-analysis and found to be significantly reduced after intensive BP control [24].”
Mousavi, A., Shojaei, S., Abhari, A. P., Mirhosseini, S. A., Ebrahimi, R., Rajabi, E., Farooqi, M. A., Azizpour, A., Moghadam, S. A., Kuno, T., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf140 · Cited by 5
Schreib, A., Arzt, M. E., Heid, I. M., Jung, B., Böger, C. A., & Stadler, S. (2020) · Sleep Medicine X · doi:10.1016/j.sleepx.2020.100013 · Cited by 3
Diabetes type 2: conventional, social and some genetic predictors of cardiovascular death
Rymar, O. D., Щербакова, Л. В., Олеговна, Щ. А., Mustafina, S. V., Симонова, Г. И., Bakhareva, Y. S., Avdeeva, E. M., Sazonova, O. V., Maksimov, V. N., & Malyutina, S. K. (2021) · Ateroscleroz · doi:10.52727/2078-256x-2021-17-2-39-50 · Cited by 3
Bridging the Gap: Managing Hypertension in Indian Patients with Metabolic Syndrome
Hiremath, J., Wander, G. S., Dasbiswas, A., Mantri, R. R., Khan, A., Bardoloi, N., Iyengar, S. S., Kalmath, B. C., Aslam, K., Vaidyanathan, P. R., et al. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0964 · Cited by 2
Heikkala, E., Hagnäs, M. P., Jokelainen, J. J., Karppinen, J. I., Ferreira, P. H., Ferreira, M. L., & Mikkola, I. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.04.006 · Cited by 6
Sodium-Glucose Cotransporter-2 Inhibitors In Heart Failure
Kaźmierski, W., Jurek, J., Lis, P., Lis, A. E., Ziobro, A., Ziomek, M., Camlet, K., & Kocur, K. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.240 · Cited by 3
Ishikawa, S.-I., Hayashi, Y., Abe, T., & Tanaka, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328142 · Cited by 1
“The current treatment policy for hypertension is fundamentally to lower blood pressure [2], regardless of the type of medication used.”
Whelton, P. K., Bundy, J. D., & Carey, R. M. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac045 · Cited by 2
Rymar, O. D., Щербакова, Л. В., Mustafina, S. V., Dolinskaya, Y. A., Симонова, Г. И., & Malyutina, S. K. (2024) · Ateroscleroz · doi:10.52727/2078-256x-2024-20-3-319-325 · Cited by 1
Handayani, S. R., & Nurtanti, S. (2019) · Jurnal Kesehatan Masyarakat · doi:10.15294/kemas.v15i2.19459 · Cited by 2
“Blood pressure instability is still a major cause of death in patients with type II Diabetes mellitus (Liu, Pong, Gallo, Darekar, & Terra, 2019) (Wang et al., 2019).”
BackgroundPandey, A., Patel, K. V., & Verma, S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch50
Rymar, O. D., Щербакова, Л. В., Mustafina, S. V., Симонова, Г. И., Avdeeva, E. M., Dolinskaya, Y. A., & Malyutina, S. K. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-4-35-41
Ishikawa, S.-I., Hayashi, Y., Abe, T., & Tanaka, S. (2025) · medRxiv · doi:10.1101/2025.06.29.25330526
DeVaughan-Circles, A., Legaspi, A. B., Nelson, T., Yao, Y., del Águila, M. J. S., Segal, R., Donahoo, W. T., Goins, R. T., Manson, S. M., Wilkie, D. J., et al. (2025) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2025.102494
Prevention of Heart Failure in People With Diabetes
Pandey, A., & Hernandez, A. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00015-x
Metadata
- Authors
- Wang, J., Chen, Y., Xu, W., Lu, N., Cao, J., & Yu, S.
- Affiliations
- Nankai University (CN)
- Chinese PLA General Hospital (CN)
- Corresponding author
- Cao, Jian
- Yu, Shengyuan
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-04-12
- Volume
- 14
- Issue
- 4
- Pages
- e0215362
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6461269
- OpenAlex
- W2940192148
- Cited by
- 45
- References
- 55
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 8 · 2023: 5 · 2022: 8 · 2021: 2 · 2020: 12 · 2019: 1
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Special Project of Healthcare Scientific Research of Military (16BJZ15)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- intensive blood pressure lowering, type 2 diabetes, all-cause mortality, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, albuminuria, heart failure, end-stage renal disease, systolic blood pressure, cardiovascular risk stratification, antihypertensive therapy, renal protection, subgroup analysis
- MeSH terms
- Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Kidney Failure, Chronic, Male, Risk Factors, Randomized Controlled Trials as Topic, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.